Johns Hopkins All Children’s Heart Institute

The Johns Hopkins All Children’s Heart Institute is ideally positioned to advance the research enterprise in collaboration with Johns Hopkins University and other local partners. These opportunities are facilitated by the ability to provide the full spectrum of clinical care, combined with the expertise present at Johns Hopkins University in Baltimore.

Research interests span the domains of translational research and clinical research, as well as in the areas of outcomes analysis and quality improvement. Physicians at All Children’s Hospital and the Johns Hopkins Children’s Center are working together on numerous research projects.

  • View a list of Research Projects at Johns Hopkins All Children's Heart Institute.

  • Cardiology in the Young (CiTY) is the leading medical journal in world dedicated to the care of patients with pediatric and congenital heart disease. Jeffrey P. Jacobs is Editor-in-Chief of Cardiology in the Young and Allen Everett is Senior Associate Editor.
  • The World Journal for Pediatric and Congenital Heart Surgery (WJPCHS) is the leading medical journal in world dedicated to pediatric cardiac surgery. Marshall L. Jacobs is Editor-in-Chief of WJPCHS and Jeffrey P. Jacobs is an Associate Editor.
  • In February 2014, 5 of the top 10 Most-Cited Articles (and 8 of the top 20 Most-Cited Articles) in The World Journal for Pediatric and Congenital Heart Surgery (WJPCHS) were written by members of Johns Hopkins All Children's Heart Surgery. View the Most-Cited Articles as of February 1, 2014.
  • Under the leadership of James A. Quintessenza, MD, The Johns Hopkins All Children’s Heart Institute has performed innovative research to develop new options for pulmonary valve replacement. View our References about Pulmonary Valve Replacement.
  • Several members of the Johns Hopkins All Children's Heart Institute have funded peer reviewed research grants. The hyperlinks below connect to a listing of the some of these grants:
  • Institution-wide Prospective, Inception Cohort Study (iPICS). Through the successful execution of iPICS, we will be able to better explain (across a variety of important pediatric conditions for which evidence is lacking/limited) apparent discrepancies between genotype and phenotype, and to derive more clinically meaningful and accurate prognostic assessment, toward better risk-stratification. Hence, iPICS will facilitate development of, and improvement in, risk-stratified and more-personalized therapeutic approaches, thereby leading ultimately to improved outcomes in these pediatric conditions. In addition, by conducting this effort across multiple conditions of interest, iPICS offers the important potential to reveal patterns of disease and overlap not apparent from evaluation of a single disease entity. Understanding these commonalities will allow application of existing and new therapies to better and novel uses (e.g. neuroprotective agents and interventions across a variety of diseases sharing clinical/subclinical brain injury as a disease sequela in common), by generating prospective cohort-level data upon which future interventional trials can be designed.
  • Three particular iPICS studies relevant to the HI are the Cardiac Intervention (cardiac surgery, interventional catheterization and electrophysiologic studies), Pulmonary Hypertension, and Healthy (normal) sub-cohorts. Data collected for research will be comprised principally of data extracted from the medical record (including results of clinical laboratory testing and radiologic imaging results), which were generated in the scope of best/standard clinical care. Some data elements will be derived from research observations that, at the time of patient enrollment, are not part of locally-defined standard clinical care, and hence are defined as exclusively-research observations (e.g., quality-of-life questionnaire). In addition, blood samples will be collected for biospecimen banking (plasma, saliva, DNA, RNA; CSF by discard only) at informative clinical time points in the course of illness/follow-up. 
  • In the CVICU Dr. Arabela Stock, MD with Suchi Saria, PhD (Johns Hopkins Whiting School of Bioengineering), are engaged in the "Development and Validation of Physiologic Monitoring Algorithms for the Prediction of Clinically-Important Outcomes in the CVICU". In this study funded by the All Children's Foundation and in partnership with Philips, we will develop non-invasive near term predictors of adverse CVICU outcomes to reduce ICU morbidity and mortality. This study allows the capture high fidelity (MHz) physiologic monitoring data from all ACH ICU beds (146) 24 hours a day and to couple the monitoring data with outcomes from the Cerner EMR. Initial prediction outcomes are sepsis and cardiopulmonary arrest. We are currently capturing on average 3,238 patient hours of monitoring data/day.